Aimei Health Technology Co., Ltd
NASDAQ:AFJKShell Companies
-$3.66 today
- Market cap
- $73.22M
- Beta
- 0.23
- P/E (TTM)
- 34.3
- EPS (TTM)
- $0.88
Volume 0.13M
Average 0.02M
AFJK Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Aimei Health Technology Co., LtdNASDAQ: AFJK
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development remains negative
Q1 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.
Context
- Research & development increased in 0 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
What to watch
Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
Research & Development vs competitors
How AFJK compares with its peers on the latest reported figures
- AFJK's LTM Mar 2026 research & development of $0 is the highest of the 8 companies compared; the peer median is $0.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
AFJKAimei Health Technology Co., Ltd | LTM Mar 2026 | $0 | — | — | — |
KOYNCSLM Digital Asset Acquisition Corp III Class A Ordinary Shares | LTM Mar 2026 | $0 | — | — | — |
EURKEureka Acquisition Corp Class A Ordinary Share | LTM Mar 2026 | $0 | — | — | — |
| LTM Dec 2025 | $0 | — | — | 0.0% | |
UYSCUY Scuti Acquisition Corp. | LTM Dec 2025 | $0 | — | — | — |
| LTM Mar 2026 | $0 | — | — | — | |
ORIQUOrigin Investment Corp I Units | LTM Mar 2026 | $0 | — | — | — |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding AFJK) | $0 | — | — | 0.0% | |
Competitors are the stored peer set for AFJK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 |
| Gross Margin | — | — | — |
| Research & Development | 0 | 0 | 0 |
| Selling, General & Admin | 28.46K | 0 | 835.76K |
| Operating Expenses | 28.46K | 1.07M | 835.76K |
| Depreciation & Amortization | 0 | 0 | 0 |
| EBITDA | 171.39K | (1.07M) | (835.76K) |
| EBITDA Margin | — | — | — |
| Operating Income | (28.46K) | (1.07M) | (835.76K) |
| Operating Margin | — | — | — |
| Interest Income | 199.85K | 3.62M | 1.9M |
| Interest Expense | 0 | 0 | 0 |
| Other Income / Expenses | 199.85K | 3.62M | 1.9M |
| Income Before Tax | 171.39K | 2.55M | 1.06M |
| Pre-Tax Margin | — | — | — |
| Income Tax Expense | 0 | 0 | 0 |
| Net Income | 171.39K | 2.55M | 1.06M |
| Net Margin | — | — | — |
| EPS (Basic) | 0.02 | 0.28 | 0.17 |
| EPS (Diluted) | 0.02 | 0.28 | 0.17 |
| Weighted Avg Shares | 9.03M | 9.03M | 4.05M |
| Weighted Avg Shares (Diluted) | 9.03M | 9.03M | 4.05M |
Aimei Health Technology Co., Ltd
NASDAQ:AFJK
Intrinsic Alpha fair value
Locked
Current Price
$11.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.